C9122 HCPCS code: Mometasone furoate sinus implant, 10 micrograms (sinuva)
C9122 is the HCPCS Level II code for mometasone furoate sinus implant, 10 micrograms (sinuva). CMS terminated C9122 on 2021-03-31; do not bill it for later dates of service. Its Medicare coverage code is D (Special coverage instructions apply): May be covered when national or local coverage criteria are met.
Code details
| Field | Value |
|---|---|
| Section | C codes — Outpatient PPS (hospital outpatient temporary codes) |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 53 |
| BETOS category | O1E — Other drugs |
| Added | 2020-07-01 |
| Last action effective | 2021-04-01 |
| Terminated | 2021-03-31 |
What changed for C9122
- 2020-07-01: C9122 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code C9122?
C9122 is the HCPCS Level II code for mometasone furoate sinus implant, 10 micrograms (sinuva). Short descriptor: "Mometasone furoate (sinuva)".
Does Medicare cover C9122?
Coverage code D — Special coverage instructions apply. May be covered when national or local coverage criteria are met.
Related C91 codes
- C9101 — Injection, oliceridine, 0.1 mg
- C9113 — Injection, pantoprazole sodium, per vial
- C9121 — Injection, argatroban, per 5 mg
- C9132 — Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity
- C9133 — Factor ix (antihemophilic factor, recombinant), rixubis, per i.u.
- C9134 — Factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.
- C9135 — Factor ix (antihemophilic factor, recombinant), alprolix, per i.u.
- C9136 — Injection, factor viii, fc fusion protein, (recombinant), per i.u.
- C9137 — Injection, factor viii (antihemophilic factor, recombinant) pegylated, 1 i.u.
- C9138 — Injection, factor viii (antihemophilic factor, recombinant) (nuwiq), 1 i.u.
- C9139 — Injection, factor ix, albumin fusion protein (recombinant), idelvion, 1 i.u.
- C9140 — Injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u.
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under C9122
- Watch C9122 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for C9122
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.